News for Co-Diagnostics, Inc. (0A50.L)

Salt Lake City, Utah, May 14, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. ( CODX) (the ”œCompany” or ”œCo-Dx”), a molecular diagnostics company with a

Co-Diagnostics, Inc. (CODX) to participate in the D. Boral Capital Inaugural Global Conference on May 14, 2025, in New York City. The conference will fe

Release Date: May 08, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Co-Diagnostics In

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NCODX.OQ - Co-Diagnostics IncQ1 2025 Co-Diagnostics Inc Earnings CallMay 08, 2025 / 08:30PM GMT

CoDiagnostics (CODX) delivered earnings and revenue surprises of 27.27% and 86.84%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

SALT LAKE CITY, May 08, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. ( CODX), a molecular diagnostics company with a unique, patented platform for the develo

Revenue: $0.1 million, significantly below the estimated $0.38 million, reflecting a decline from $0.5 million in Q1 2024 due to timing of grant revenue recogn

Co-Diagnostics (CODX) will release its first quarter 2025 earnings on May 8, 2025, after market close. A conference call and webcast will occur at 4:30 p.m.

Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiation...

Total Revenue: $3.9 million for fiscal year 2024, down from $6.8 million in the prior year.Grant Revenue: $3.1 million in 2024.Product Revenue: $0.8 million in

Mar 27, 2025 / 08:30PM GMTOperator Good day, and welcome to the Co-Diagnostics fourth quarter and full year 2024 earnings conference call. (Operator Instruction

CoDiagnostics (CODX) delivered earnings and revenue surprises of -5.88% and 60.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

PR NewswireSALT LAKE CITY, March 27, 2025 SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics compa

Revenue: $3.9 million for the full year 2024, falling short of the annual estimate of $4.14 million.Net Loss: $37.6 million, compared to a net loss of $35.3 mi

PR NewswireSALT LAKE CITY, March 13, 2025 SALT LAKE CITY, March 13, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics compa

PR NewswireSALT LAKE CITY, March 3, 2025 The symposium exploring advances in cancer prevention and care is set to take place on March 4, International HPV

PR NewswireSALT LAKE CITY, Jan. 7, 2025 SALT LAKE CITY, Jan. 7, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a m

Total Revenue: $0.6 million, down from $2.5 million in the prior year same period.Grant Revenue: $0.4 million in the third quarter of 2024.Product Revenue: $0.

Co-Diagnostics, Inc. (NASDAQ:CODX) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ETCompany ParticipantsAndrew Benson - Head of Investor...